Guggenheim reiterates Enliven Therapeutics stock rating on FDA alignment
Covered in this story
What has happened since
- Enliven Therapeutics Inc is down 3.3% since this was published, 6 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Guggenheim’s $78 target on $ELVN is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Guggenheim’s track record →Analyst targets on Enliven Therapeutics Inc
- Morgan Stanley: $47 → $70 by Oct 2027 · Overweight via Investing.com
- JPMorgan: $46.2 → $75 by Oct 2027 · Overweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ELVN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Enliven Therapeutics Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.